iSTAR's MINIject shows positive 18-month results

iSTAR Medical’s MINIject device showed positive results in a first-in-human trial, with a mean pressure reduction of 15 mm Hg at 18 months, according to a press release.

The 18-month results of the STAR-I clinical trial are consistent with results reported at 1 year.

Nearly two-third of patients who received the MINIject device, which reduces IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space, were able to cease eye drop usage as well, the release said.

“We are thrilled to see MINIject’s powerful and reliable efficacy in a stand-alone procedure sustained over time, without a trade-off between safety and efficacy, and without requiring invasive follow-up procedures or surgeries,” iSTAR Medical CEO Michel Vanbrabant said in the release. “We look forward to bringing this therapeutic option in the supraciliary space to market for glaucoma patients.”

iSTAR Medical’s MINIject device showed positive results in a first-in-human trial, with a mean pressure reduction of 15 mm Hg at 18 months, according to a press release.

The 18-month results of the STAR-I clinical trial are consistent with results reported at 1 year.

Nearly two-third of patients who received the MINIject device, which reduces IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space, were able to cease eye drop usage as well, the release said.

“We are thrilled to see MINIject’s powerful and reliable efficacy in a stand-alone procedure sustained over time, without a trade-off between safety and efficacy, and without requiring invasive follow-up procedures or surgeries,” iSTAR Medical CEO Michel Vanbrabant said in the release. “We look forward to bringing this therapeutic option in the supraciliary space to market for glaucoma patients.”